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Coreceptor switchThe molecular mechanism(s) underlying transition from CCR5 to CXCR4 usage of subtype C viruses remain
largely unknown. We previously identiﬁed a subtype C HIV-1 infected child whose virus demonstrated
CXCR4 usage along with CCR5 upon longitudinal follow-up. Here we delineated the molecular determinants
of Env involved in expanded coreceptor usage. Residue changes in three positions of Env V3 domain are
critical for the dual tropic phenotype. These include: substitution of arginine at position 11, MG or LG
insertion between positions 13 and 14, and substitution of threonine at the position immediately
downstream of the GPGQ crown. Introducing these mutations into V3 region of a heterologous R5 virus also
conferred dual tropism. Molecular modeling of V3 revealed a possible structural basis for the dual tropic
phenotype. Determining what deﬁnes a subtype C X4 virus will lead to a better understanding of subtype
C HIV-1 pathogenesis, and will provide important information relevant to anti-retroviral therapy., School of Biological Sciences,
x 830666, Lincoln, NE 68583-
.
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Background
HIV-1 enters host cells through a complex and dynamic process
whereby envelope (Env) glycoprotein 120 (gp120) binds sequentially
to CD4 and a coreceptor, typically CCR5 or CXCR4 (Alkhatib et al.,
1996; Choe et al., 1996; Deng et al., 1996; Doranz et al., 1996; Dragic
et al., 1996; Feng et al., 1996). Based on coreceptor usage in vitro, the
majority of HIV-1 variants can be classiﬁed into three categories:
CCR5-using viruses were designated as R5, CXCR4-using viruses, X4,
and viruses able to use both receptors, R5X4 (Berger et al., 1998).
These patterns of coreceptor usage usually correspond to the
phenotypes deﬁned by the formation of syncytia in MT-2 cell line,
where syncytia-inducing (SI) viruses were able to use CXCR4, while
nonsyncytia-inducing (NSI) viruses used CCR5 (Bjorndal et al., 1997).
Transmission of HIV-1 is, in general, associated with viruses that
utilize CCR5, which predominate during the acute and asymptomatic
phases of infection (Michael et al., 1997; Rana et al., 1997). Disease
progression is often related to the emergence of viruses that have
acquired the ability to use CXCR4 (Connor et al., 1997; Scarlatti et al.,
1997). The appearance of CXCR4-using viruses was associated with an
accelerated rate of loss of CD4+ T cells and a relatively rapid
progression to AIDS and death (Karlsson et al., 1994;Maas et al., 2000;
Richman and Bozzette, 1994; Schuitemaker et al., 1992).Coreceptor usage and switching have been extensively studied
in subtype B HIV-1 isolates. Some of the features of the Env
glycoprotein involved in coreceptor usage have been revealed. It is
known that HIV-1 cellular tropism and coreceptor speciﬁcity are
largely determined by the third hypervariable loop (V3) of the viral
gp120 glycoprotein, and distinct changes in this region and higher
positive charges are associated with CXCR4 coreceptor usage among
subtype B viruses (Cocchi et al., 1996; De Jong et al., 1992; Hoffman
and Doms, 1999; Hung et al., 1999; Hwang et al., 1991; Pollakis et al.,
2001; Shioda et al., 1991; Westervelt et al., 1992). In addition to V3,
other regions in gp120, such as V1/V2 and C4, have also been
implicated in CXCR4 usage (Carrillo and Ratner, 1996; Hoffman et al.,
2002; Labrosse et al., 2001; Nabatov et al., 2004; Ogert et al., 2001;
Pastore et al., 2006). A recent study indicated that gp41 transmembrane
subunit was also involved in CXCR4 utilization (Huang et al., 2008).
Subtype C HIV-1 is currently responsible for the vast majority of
new HIV-1 infections worldwide and is now the most prevalent
subtype (http://www.unaids.org). In sub-Saharan Africa, subtype C
HIV-1 accounts for more than 60% of infections and a signiﬁcant
number of infections are in infants and children (Papathanasopoulos
et al., 2003). However, factors that contribute to the continuing
expansion of subtype C viruses have yet to be clearly elucidated. Prior
studies have suggested that CXCR4-using viruses were infrequently
identiﬁed in subtype C HIV-1 infection compared to subtype B (Abebe
et al., 1999; Bjorndal et al., 1999; Cecilia et al., 2000; Choge et al.,
2006; Cilliers et al., 2003; McCormack et al., 2002; Morris et al., 2001;
Ndung'u et al., 2006; Ping et al., 1999; Pollakis et al., 2004; Zhang et al.,
2006). Consequently, molecular mechanism(s) underlying the tran-
sition from R5 to X4 usage of subtype C virus remains largely
Fig. 1. Coreceptor usage of HIV-1 quasispecies from 42 and 48 months after birth of
child 1690. The infectivity mediated by the 42 or 48-month viral isolates was measured
in U373-MAGI target cells expressing CD4 and either CCR5 or CXCR4. Infection with
virus SF128A, NL4-3 or 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage
virus, respectively. The results are representative of two independent experiments, and
the error bars represent standard deviations.
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accumulating evidence has now shown that there is an increase in
frequency in the detection of CXCR4-using subtype C HIV-1. A recent
study from South Africa reported that CXCR4-using viruses were
detected in 30% of a drug-naïve AIDS cohort, suggesting an ongoing
dynamic evolution and maturing of the subtype C epidemic in South
Africa (Connell et al., 2008; Michler et al., 2008). In addition, the
emergence of the X4 viruses was found in about 50% of subtype C
infected patients receiving partially suppressive anti-retroviral ther-
apy (ART) (Johnston et al., 2003; Kassaye et al., 2009; Tsibris et al.,
2008). This suggests that ART could promote the emergence of
CXCR4-using virus. Although the sample size is relatively small in
those studies, the introduction of anti-retroviral therapy is likely to
change the subtype C HIV-1 epidemic in Africa and the coreceptor
usage of this subtype (Johnston et al., 2003; Kassaye et al., 2009;
Mosier, 2009; Tsibris et al., 2008).
Todatemost of the studies regarding subtypeC coreceptor switching
mainly focus on genetic characterization of the viruses, and only a few
documented the biological properties of these viruses (Abebe et al.,
1999; Bjorndal et al., 1999; Cecilia et al., 2000; Choge et al., 2006; Cilliers
et al., 2003; Coetzer et al., 2006; Connell et al., 2008; McCormack et al.,
2002;Michler et al., 2008;Morris et al., 2001; Ndung'u et al., 2006; Ping
et al., 1999; Pollakis et al., 2004; Raymondet al., 2010; Singh et al., 2009;
Zhang et al., 2006). Moreover, the prediction of coreceptor tropismwas
mainly derived from the quasispecies rather than cloned viruses, and
the molecular determinants that could govern subtype C HIV-1
coreceptor switch have not yet been deciphered experimentally. The
appearance of X4 virus has been associatedwith poor clinical prognosis,
and treatmentwith CCR5 inhibitorsmay select for CXCR4-using viruses,
therefore, determining what deﬁnes a subtype C X4 virus and
phenotypic characteristics of the virus will lead to a better understand-
ing of the factors involved in pathogenesis and disease progression of
subtype C HIV-1, and will provide important information relevant to
anti-retroviral therapy as well.
We have previously characterized the longitudinal variations of
the HIV-1 viral envelope glycoprotein obtained from a panel of HIV-1
infected children over a four-year follow-up period, and have
identiﬁed a subtype C HIV-1 perinatally infected child whose virus
had demonstrated CXCR4 usage in addition to CCR5 at 48 months
after birth (Zhang et al., 2006). This case provides us with an
invaluable resource to study the evolution of coreceptor usage and to
elucidate the molecular determinants of CXCR4 usage in the context
of subtype C HIV-1 in an anti-retroviral naïve individual. To
understand the basis for the expanded coreceptor usage, here we
analyzed the sequence variations of the viral Env from the
longitudinal follow-up samples and identiﬁed the molecular deter-
minants of subtype C HIV-1 coreceptor transition from R5 to R5X4.
Results
Variants with distinct changes in the Env V1–V5 regions appeared at the
time of detection of the virus with the expanded coreceptor usage
Child 1690 was found to be HIV-1 positive at 12 months after birth
and anti-retroviral naïve throughout the study. The R5 coreceptor
tropism was maintained at 12, 24, 36 and until 42 months after birth;
after which, the viral isolate from 48 months was found to use CXCR4
in addition to CCR5, and infected both macrophages and MT-2 T
lymphoblasts where it formed syncytia [(Zhang et al., 2006) and data
not shown]. We further tested the coreceptor preference of the
primary isolates from 42 and 48 months in U373-MAGI indicator cells
which express CD4 and either CCR5 or CXCR4. The 48-month isolate
was able to infect either CCR5 or CXCR4-expressing cells, whereas the
42-month isolate only exhibited CCR5-mediated infection (Fig. 1).
In order to identify the molecular determinants of the expanded
coreceptor usage of the 48-month isolate, we analyzed changes of theviral Env sequences from 12, 24, 36, 42 and 48 months of follow-up.
Sequence analysis of the Env V1–V5 region indicated that there were
distinct changes in the Env glycoprotein, mainly in the V3 and V4
regions, among clonal variants before (12, 24, 36 and 42 months) and
after (48 months) NSI to SI or CCR5 to CCR5/CXCR4 phenotype switch
(Fig. 2 and data not shown).
We ﬁrst examined the sequence of the V3 region as this region
signiﬁcantly inﬂuences and determines coreceptor preference of non-
subtype C HIV-1. Compared to the subtype C consensus, the V3 loops of
all R5 viruses from12 and 42 monthswere 34 amino acids in length and
contained the GPGQmotif at the crown, characteristic of HIV-1 subtype
C viruses (Fig. 2A). A neutral serine (S) residue was completely
conserved at position 11 among 12 or 42-month variants. Sequence
analysis of 48-month variants indicated that 46% of sequences (13 of 28
clones sequenced) harbored the V3 region sequences which are similar
to those of 12 or 42-month variants, with a net charge of +5 in the V3
region, indicative of R5 usage (Fig. 2A). However, the remaining 54% of
sequences (15 of 28 clones) of 48-month variants showed distinct
changes in theV3 loop.Notably, an insertion of two aminoacids— either
MG or LG upstream of the GPGQ crown (between positions 13 and 14)
was observed. In addition, mutations within the V3 region of these 48-
month variants also include the change at position 11 from a neutral
serine to a positive arginine (R), which was reported to associate with
CXCR4 usage of subtype B HIV-1, and resulted in an increased positive
charge (+6). Moreover, we also identiﬁed changes immediately
downstream of the GPGQ crown from a valine (V) or alanine (A) to
threonine (T). Interestingly, all the changes in the V3 domain as
described previously were linked to each other in 54% of sequences (15
of 28 clones) from 48-month variants, indicating possible functional
association of these changes. Based on these observations, we
anticipated that a mixture of R5 and either dual R5X4 or X4 variants
could co-exist in the 48-month variants.
Moreover, we also determined whether non-V3 regions also
possessed unique sequences suggestive of expanded coreceptor usage.
Sequence analysis showed that there were some speciﬁc changes in the
V4 region which co-evolved with the changes in the V3 region.
In particular, a loss of a potential N-linked glycosylation site at the N-
terminal of V4 region (mainly fromNTS toNTA)was noted in all but one
(14 out of 15 clones, 93%) variantswhichhave predictedR5X4or CXCR4
usage based on V3 sequence analysis (Fig. 2B). This N-linked glycanwas
completely conserved in 12-month sequences and maintained in the
majority of the 42-month sequences and 48-month variants with
Fig. 2. Comparison of sequences from child 1690 at different time points. A. Consensus V3 amino acid sequence for variants at 12 and 42 months (12m_CON and 42m_CON),
respectively. Predicted V3 sequence for variants at 48 months (48m) with the number in parenthesis indicating the number of clones that contain the speciﬁc signature sequence. In
all cases the sequences are compared to a HIV-1 subtype C consensus sequence. B. Comparison of the potential N-linked glycosylation site at the N-terminal of the V4 region. The loss
of this glycan among all but one (14 out of 15) of the 48-month variants which have predicted CXCR4 usage based on V3 sequence analysis is in italics.
70 H. Zhang et al. / Virology 407 (2010) 68–79predicted CCR5 utilization based on V3 sequence analysis (Fig. 2B).
These ﬁndings on the association of the linked changes in the V3 and V4
regions suggest a possible functional relationship between the V3 and
V4 regions.
Coreceptor usage of the molecularly cloned chimeric viruses
To test whether the characterized Env sequences possess the
predicted coreceptor usage, we created chimeric proviral constructs
by introducing subtype C Env V1–V5 fragments from child 1690 into a
proviral expression vector with the subtype B (NL4-3) backbone.
Multiple representative Env clones with the signature sequences as
described previously were selected from time points at 42 and
48 months before and after the expanded coreceptor usage.
The coreceptor usage of the resulting representative chimeras was
evaluated in indicator Ghost 3 cells. Infection with virus SF128A, NL4-
3 or 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4-using
virus, respectively. The CXCR4 usage of the virus was conﬁrmed by
syncytium formation inMT-2 cells. Consistent with what we observed
for the primary isolates, chimera 42m-74 which contains Env V1–V5
signature sequences from 42-month time point exhibited CCR5
tropism and did not form syncytia in MT-2 cells (Fig. 3). In contrast,Fig. 3. Amino acid comparison of the V3 sequences and coreceptor utilization of the represen
transfection of 293 T cells. An equal quantity of TCID50 for each virus was added to Ghost 3 ce
integrated LTR-GFP cassette was used to assign positive or negative value after ﬂuorescen
syncytia formation at day 6 post-infection. Infection with virus SF128A, NL4-3 and 89.6 serve
in the three positions that may affect the coreceptor usage are indicated by arrows.chimeras derived from 48-month viral sequences bearing insertions
in V3 and other linked changes in the V3 and V4 regions as described
previously (48m-7 and 48m-18) caused syncytia in MT-2 cells and
could infect both CXCR4 and CCR5-expressing target cells (Fig. 3).
However, Env chimeras which failed to infect MT-2 cells but
could infect CCR5-expressing target cells were also identiﬁed among
48-month Env derivatives (Fig. 3, 48m-30). As expected, the CCR5-
using 48-month chimeras share similar signature sequences with the
42-month chimeras (Fig. 3, 42m-74 versus 48m-30). Taken together,
our phenotypic analyses of the 48-month sample revealed heteroge-
neous viral populations comprising both R5 and R5X4 tropic variants.
We further conﬁrmed the coreceptor usage of the representative
variants by infecting TZM-bl cells, which express both coreceptors, in
the presence of a CXCR4 or CCR5 inhibitor (Fig. 4A). Infection of TZM-
bl cells by control NL4-3 was efﬁciently blocked by the CXCR4
antagonist AMD3100 and unaffected by CCR5 inhibition, as expected
for a CXCR4-dependent strain. In contrast, SF128 Awas not affected by
CXCR4 blockade but was blocked by the CCR5 antagonist TAK 779, as
expected for an R5 strain. Consistent with observations by others
(Maeda et al., 2008), the dual tropic virus 89.6 was efﬁciently
inhibited by AMD 3100 but not by TAK 779. Variants 18 and 7 from
48-month follow-up were almost completely blocked by the CCR5tative viruses from 42 and 48 months. Chimeric viruses and controls were produced by
lls expressing the indicated coreceptors. GFP expression induced by Tat activation of the
t microscopic examination at day 4 post-infection. MT-2 infection was monitored for
d as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. Residue changes
Fig. 4. Coreceptor preference of representative chimeric proviruses. A. Coreceptor usage of 42-month and 48-month variants of child 1690 was determined by entry inhibition into
TZM-bl cells with 1 μM CXCR4 inhibitor (AMD 3100) or CCR5 inhibitor (TAK-779). Viruses SF128A, NL4-3 and 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus,
respectively. B, C. Infection and blocking with cognate coreceptor inhibitor were performed in U373-MAGI-CCR5 (B) or U373-MAGI-CXCR4 (C) cells. Viruses SF128A, NL4-3 and 89.6
served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. The data are expressed as mean values from experiments performed in triplicate, and the error bars
indicate standard deviations.
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efﬁciently (70% inhibition), suggesting the dual CCR5/CXCR4 usage. In
contrast, similar to 42-month variant 74, variant 30 from 48-month
follow-upwas essentially fully blocked by TAK 779 but not affected by
AMD 3100, resembling the R5 phenotype (Fig. 4A). The dual tropic
phenotype of variant 48m-18 was reinforced by the infection and
blocking experiments in U373-MAGI indicator cells, where the virus
was able to infect either CCR5 or CXCR4-expressing cells, and was
completely inhibited by the cognate coreceptor inhibitor with the
respective cell lines (Figs. 4B and C). Whereas, variant 48m-30
consistently showed CCR5-dependence as indicated by an effective
inhibition of infection in U373-MAGI-CCR5 cells by TAK 779 (Fig. 4B).
V3 domain is necessary and sufﬁcient to confer the expanded coreceptor
usage of the 48-month isolate
Our sequence analyses have indicated that some potential sites in
V3 and V4 regions may be involved in the expanded coreceptor usage
of the 48-month isolate. To better understand the impact of the V3
and V4 regions on coreceptor switch, we constructed chimeric env
clones by exchanging the V3 or V4 region between the 48-month dual
CCR5/CXCR4-using variant 48m-18 and CCR5-using variant 48m-30
(Fig. 5A). The coreceptor usage of the resulting chimeras was
evaluated by infection assays using Ghost 3 cells and MT-2 cells as
described previously. We found that the chimera 30-V3-18 which
contains the V3 region from R5-tropic variant 48m-30 in the context
of R5X4 env backbone (variant 48m-18) failed to infect CXCR4-expressing target cells, did not form syncytia in MT-2 cells, and only
exhibited CCR5 tropism (data not shown). This suggests that the V3
domain of 48m-30 confers the CCR5 coreceptor usage.
We further tested the speciﬁcity of coreceptor usage of the
chimera 30-V3-18 by infecting TZM-bl cells in conjunction with
CXCR4 and CCR5 inhibitors. Infectionwith virus SF128A, NL4-3 or 89.6
served as controls for CCR5, CXCR4 or CCR5/CXCR4-using virus,
respectively. Similar to the parental R5X4 variant 48m-18, the
infection of TZM-bl cells by the chimera 30-V3-18 was essentially
fully blocked by the CCR5 antagonist TAK 779 (Fig. 5B). However, the
infection was not blocked by the CXCR4 antagonist AMD 3100, similar
to that of the parental CCR5-using variant 48m-30 (Fig. 5B). We
therefore concluded that V3 domain is necessary and sufﬁcient to
confer the expanded coreceptor usage of 48m-18. In contrast, the
chimera 30-V4-18, that contained the V4 region from R5-tropic
variant 48m-30 in the context of R5X4 env backbone of variant 48m-
18 remained R5X4 tropic, suggesting that V4 region is not essential for
the expansion of coreceptor usage of the variant 48m-18 (Fig. 5B).
Infection of U373-MAGI target cells with the domain-exchanged
chimeras provided additional evidence of the Env V3 domain as a
major determinant of R5X4 usage. As shown in Fig. 5C, the chimera
30-V3-18 only displayed CCR5-mediated infection in CCR5-expres-
sing target cells, albeit less efﬁcient than the parental R5 tropic variant
48m-30. In contrast, the V4 domain-swapped chimera 30-V4-18
mediated similar level of infection in either CCR5 or CXCR4-
expressing cells compared to the parental dual tropic virus 48m-18
(Fig. 5C).
Fig. 5. The impact of the V3 and V4 regions on the coreceptor usage. A. Schematic representation of the V3 or V4 domain-swapped chimeras. V3 or V4 region from R5 clone 48m-30
was introduced into the env backbone of R5X4 clone 48m-18 to generate the domain-swapped chimeras 30-V3-18 or 30-V4-18. The coreceptor utilization of each virus is indicated.
B. Coreceptor usage of the 48-month parental variants (48m-30 and 48m-18) and env chimeras (30-V3-18 and 30-V4-18) was determined by entry inhibition into TZM-bl cells with
1 μM CXCR4 inhibitor (AMD 3100) or CCR5 inhibitor (TAK 779). Viruses SF128A, NL4-3 and 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. C. The
infectivity mediated by the 48-month parental variants and the V3 or V4 domain-swapped chimeras was measured in U373-MAGI target cells expressing CD4 and either CCR5 or
CXCR4. Infection with virus SF128A, NL4-3 or 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. The results are representative of three independent
experiments, and the error bars represent standard deviations.
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for the expanded coreceptor usage
To identify the molecular determinants of CCR5/CXCR4 utilization,
we performed site-directed mutagenesis to change the residues at the
three positions (R, MG and T) in the V3 region of variant 48m-18 to
resemble the amino acids observed in the R5 variants as shown in
Fig. 6A. Since A and V co-existed among the R5 variants at similar
frequency, we changed T to A for the convenience of mutagenesis. The
coreceptor usage of each resultingmutant was ﬁrst evaluated in Ghost
3 cells and MT-2 cells. Notably, when single or combinations of
mutations in the V3 region were introduced, all the mutants failed to
infect CXCR4-expressing target cells, and only exhibited CCR5
tropism. This is consistent with the observations that none of the
mutants was able to form syncytia in MT-2 cells (Fig. 6A).
We further analyzed the infection of these mutants in U373-MAGI
cells (Fig. 6B). As expected, the infection of all the mutants in 373-MAGI-CXCR4 cells was abrogated. Therefore, we conclude that, in the
context of the 48m-18 V3 loop, the presence of R, MG and T was
critical for envelope interaction with CXCR4 coreceptor, and the
residues at those three positions are the minimal determinant for the
CXCR4 usage.
Positively selected sites
To directly examine the molecular evolution of HIV-1 in the
context of coreceptor usage, we estimated the selection pressure
acting across residues within the V3 domain. Only two residues
showed evidence for positive selection as indicated by the rate of
nonsynonymous and synonymous substitutions (dN/dS). The residue
immediately downstream of the GPGQ crown, which was an A, V or T
was found to have a dN/dS ratio of 7.4 (p=0.087). Furthermore, an
S11R substitution had a dN/dS value of 4.50 albeit with a higher
probability (p=0.283).
Fig. 6. Single and combinations of mutations within the V3 region of R5X4 virus 48m-18 and coreceptor utilization of the resulting V3 mutant chimeric viruses. A. GFP expression in
Ghost 3 cells expressing the indicated coreceptors was used to assign positive or negative value after ﬂuorescent microscopic examination at day 4 post-infection. MT-2 infection was
monitored for syncytia formation at day 6 post-infection. Mutations in the three positions are indicated by arrows. B. Infectivity mediated by mutants containing single or
combinations of mutations within the V3 region in the backbone of R5X4 virus 48m-18 was measured in U373-MAGI target cells expressing CD4 and either CCR5 or CXCR4. Infection
with virus SF128A, NL4-3 or 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus, respectively. The results are representative of three independent experiments, and
the error bars indicate standard deviations.
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coreceptor usage
We next evaluated whether introduction of the mutations in the
three positions in the V3 region could confer the dual tropic
phenotype on a different HIV-1 genetic background. We selected
another HIV-1 subtype C R5 variant, 1984i48m-18, that was derived
from child 1984 at 48 months after birth, and introduced those
mutations into its V3 region (Fig. 7A). We found that the mutations in
the V3 region enabled the virus to form syncytia inMT-2 cells (Fig. 7A)
and infect CCR5 or CXCR4-expressing target cells (Fig. 7B). Thus, the
presence of R, MG and T in the V3 region also conferred the dual
tropism in a heterologous viral context.
V3 sequence comparison between the R5X4-using viruses in the present
and published studies
To address the biological relevance of our ﬁndings, and to further
validate and conﬁrm our results indicating that the V3 region is a
major determinant for coreceptor usage of subtype C viruses, we
compared the sequences of our R5X4 virus with those of subtype C
R5X4 or X4 virus in the HIV-1 database or published literature to see
whether the amino acids of interest are conserved. Sequence
comparison revealed a strong homology in the V3 domain between
our R5X4 virus and the published dual tropic or X4 tropic virus(Fig. 8). The two amino acid insertions upstream of the GPGQ crown
(between positions 13 and 14) and the amino acid substitution of T
immediately downstream of the GPGQ crown (position 21) were
present in the majority of the sequences of R5X4 and X4 viruses.
Nineteen of the 36 dual tropic viruses (53%) had the two amino acid
insertions, mainly IG, and 17 of the 36 viruses (47%) had the threonine
substitution (Fig. 8A). A similar frequency in those changes was also
observed for the X4 viruses, with 59% of X4 viruses (22 in total)
harboring the two residue insertions and 50% of the viruses having the
threonine substitution, respectively (Fig. 8B). The high sequence
similarity in the V3 region among those CXCR4-using viruses
indicated that the V3 region could be a major determinant that
governs the coreceptor usage in a majority of the subtype C viruses
with CXCR4 usage. Another important feature in the V3 region
associated with CXCR4 usage is the arginine substitution in the GPGQ
crown, mainly at position 18 or 20 (Figs. 8A and B) although this
residue substitution is absent from our dual tropic viruses.
Molecular modeling of V3 structure
To evaluate the possible inﬂuences of those mutations observed in
the V3 region on the structure of V3 in the context of gp120, we
introduced the sequences of the 48-month dual tropic variant 48m-18
and CCR5-using variant 48m-30 into the X-ray crystal structures of
V3-containing gp120 core (Huang et al., 2005), respectively (Fig. 9).
Fig. 7. Effects of V3 mutations on coreceptor usage of unrelated subtype C HIV-1. A. The predicted V3 amino acid sequences of a 48-month variant of child 1984 and the V3 mutant.
MT-2 infection was monitored for syncytia formation at day 6 post-infection. B. The coreceptor utilization of the 48-month parental variant and the V3 mutant was determined in
U373-MAGI target cells expressing CD4 and either CCR5 or CXCR4. Infection with virus SF128A, NL4-3 and 89.6 served as controls for CCR5, CXCR4 or CCR5/CXCR4 usage virus,
respectively. The results are representative of two independent experiments, and the error bars represent standard deviations.
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48m-18 could increase the bulkiness of the V3 tip and may introduce
structural stress in the V3 tip. As a result, it could disrupt the hydrogen
bond between F317 and R308, and the hydrogen bond between F317
and Y318, thereby changing the rigidity and increasing the ﬂexibility
of the V3 tip (Fig. 9E).
We further compared the surface electrostatic potential of the two
variants with different coreceptor preference (Figs. 9C–D, F–G). AnFig. 8. Sequence variation in the V3 region of HIV-1 subtype C R5X4 and X4 viruses from
whereas the symbol height (Y axis) indicates the relative frequency of each amino acid atextended positively charged area was observed in the V3 tip of the
dual tropic variant 48m-18 due to the substitution of the positively
charged arginine at position 306 (Figs. 9F versus C). In addition, a
negatively charged cavity on the other side of the V3 tip, resulting
from the MG insertion, was also apparent in the R5X4 variant 48m-18
compared to the R5 variant 48m-30 (Figs. 9G versus D). Therefore, the
differences in the ﬂexibility and charge distribution of the V3 tip may
account for the observed coreceptor preference of these two variants.HIV-1 database and published literature. The X axis indicates the amino acid position,
that position of 36 R5X4 viruses (A) and 22 X4 viruses (B).
Fig. 9. V3 sequence and structure modeling. A. Alignment of V3 sequence of HXB2, 48m-30 and 48m-18 variants. The numbering of the gp120 residues corresponds to that of HXB2.
The two residue insertions in 48m-18 are colored red. B–G. V3 structures of the R5 variant 48m-30 (B–D) and the dual tropic variant 48m-18 (E–G) are modeled with Swiss-Model
(http://swissmodel.expasy.org) using 2B4C as the template (Huang et al., 2005). The protein backbone models show structural differences between variants 48m-30 (B) and 48m-
18 (E). The insertions in 48m-18 are indicated by red annotation (M309 and G310). Hydrogen bonds within backbone atoms are indicated by the orange dashed lines. The asterisks
indicate the hydrogen bonds lost in 48m-18 but present in 48m-30. The surface models show the electrostatic force distribution of variants 48m-30 (C, D) and 48m-18 (F, G). The
models B and C or E and F are in the same view angles. Models D and G are rotated 180° about the vertical axis. The scale of the electrostatic forces is between−2.000 (red, negative
charge) and +2.000 (blue, positive charge). The white area represents neutral charge.
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The pathogenic signiﬁcance of coreceptor switch in HIV-1 infection
is not completely understood. This situation is more complex in
subtype C infection as limited information is available, especially
regarding longitudinal isolates that showed coreceptor switching over
time. In this study, we generated a set of molecularly cloned viruses
from an infected child and delineated the molecular feature for the
transition from CCR5 to dual CCR5/CXCR4 utilization of subtype C
variants during longitudinal follow-up. However, we were not able to
follow up the child beyond 48 months to determine whether the virus
had eventually become exclusively X4 tropic.
The central role of the V3 loop in HIV-1 coreceptor usage has been
well established for subtype B viruses. However, the genetic
determinants associated with subtype C coreceptor utilization have
not been deﬁned at the clonal level, although several studies have
described the potential molecular features, particularly in the V3
domain, that could inﬂuence subtype C virus coreceptor tropism
(Cilliers et al., 2003; Coetzer et al., 2006; Raymond et al., 2010; Singh
et al., 2009). Our study, by swapping the V3 loop between the CCR5
and dual tropic variant, clearly indicated that consistent with non-
subtype C viruses, V3 loop is a principal determinant for coreceptor
usage of subtype C viruses. Therefore, the key role of V3 loop in
governing HIV-1 coreceptor utilization could be a common mecha-
nism among different subtypes, although regions other than V3 loop
could also be involved in this process. In addition, we found that in the
context of the dual tropic virus, V4 region is not essential for the
expanded coreceptor usage. But it is possible that the co-evolving
residues in V4 may act as compensatory or stabilizing mutations to
accommodate some of the functional constraints imposed by thesequence variation observed in V3. Alternatively, the variations in V4
could directly or indirectly inﬂuence other biological properties of the
Env. The signiﬁcance of the co-variation of the V3 and V4 domains is
currently under investigation.
We further analyzed the residues within V3 domain that were
critical for the R5X4 dual tropic phenotype of the subtype C viruses.
Different rules of estimating coreceptor tropism have been published
based on the amino acid sequence of the Env V3 region. Among these,
themost widely used is the 11/25 rule, where acquisition of positively
charged residues at either amino acid position 11 or 25 in V3 was
associated with CXCR4 usage (De Jong et al., 1992; Milich et al., 1997).
Recently, bioinformatics driven prediction systems have been devel-
oped (Jensen et al., 2006, 2003). In this study, we found that a
positively charged residue arginine was present at position 11 of the
dual tropic variants. However, this positively charged residue is
important (Fig. 6B, mutant 48m-18-S) but not sufﬁcient (Fig. 6B,
mutant 48m-18-ΔMGA) for CXCR4 utilization in the context of the
variant 48m-18. In addition, the positively charged residue at position
25 was absent in all of the variants having the predicted dual tropic
phenotype including 48m-18. Consistent with reports for subtype B
(Fouchier et al., 1992; Shioda et al., 1994), we observed a correlation
between the increased positive charge of V3 loop and CXCR4 tropism,
with the CXCR4-using viruses having higher positive charge (+6)
compared to CCR5-using viruses (+5), suggesting a possible common
feature for coreceptor switch among viruses from different subtypes.
The second signiﬁcant change in the V3 region contributed to CXCR4
usage was the insertion of either MG or LG between positions 13 and
14. Removal of this insertion abolished CXCR4 utilization by the virus
(Fig. 6B), indicating the critical role of this insertion in the dual
coreceptor tropism of subtype C viruses. One or two amino acid
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subtype C X4 viruses (Cilliers et al., 2003; Coetzer et al., 2006;
Raymond et al., 2010; Singh et al., 2009), but our study is the ﬁrst to
experimentally verify the signiﬁcance of the insertions for the
expanded CXCR4 tropism. Another genetic feature in the V3 region
related to the dual tropic subtype C viruses was the amino acid
substitution by T immediately downstream of the GPGQ crown.
Similar to the other two mutations, this residue is required but
insufﬁcient in conferring the dual tropism of the viruses (Fig. 6B).
The importance of this amino acid substitution in determining
coreceptor preference has not been indicated in previous studies.
However, A-to-T substitution has been implicated in escape from
certain neutralizing antibody (Reitz et al., 1994), and also found to
contribute to the acquired replication in the thymus in vivo but not in
macrophage (Miller et al., 2001). Interestingly, our selection analysis
revealed that the amino acid substitution by T at this position was
under strong positive selection, with an estimated dN/dS value of 7.4,
suggesting that the presence of T at this site may be essential for the
binding to both CCR5 and CXCR4. Therefore, the three mutations in
the V3 region (R, MG and T) collectively contribute to CXCR4
engagement. More importantly, introducing the three mutations
into a heterologous subtype C R5 variant was also sufﬁcient in
imparting the expanded CXCR4 tropism.
It has been suggested that coreceptor switching occurs less
frequently for subtype C viruses compared to subtype B viruses. The
intrinsic differences in V3 conformation between the two subtypes
could be responsible for the limited CXCR4 adaptation for subtype C
virus (Patel et al., 2008). It is also possible that the more complex
genetic pathway with more than one mutation sites needed for
efﬁcient CXCR4 usage, as indicated in this study and those of others
(Cilliers et al., 2003; Coetzer et al., 2006; Raymond et al., 2010; Singh
et al., 2009), may also contribute to the infrequent CXCR4 usage of
subtype C viruses.
The structural basis for CCR5 or CXCR4 speciﬁcity is still poorly
understood. The current model of how gp120 interacts with CCR5
suggests that the tip of V3 region of gp120 binds to the second
extracellular loop (ECL2) of CCR5, the base and stem of V3 and
bridging sheet binds to the N-terminus of CCR5 (Cocchi et al., 1996;
Cormier and Dragic, 2002; Huang et al., 2007, 2005; Rizzuto et al.,
1998). The involvement of ECLs and the N-terminal of CXCR4 in the
binding of CXCR4 was also observed (Brelot et al., 1999; Doranz et al.,
1999; Kajumo et al., 2000; Wang et al., 2004). In this study, the
mechanism by which the three mutations in the V3 loop determine
CXCR4 usage is unclear. It is possible that the structural alterations
created by MG insertion in the V3 tip may affect the interaction of the
V3 tip with ECL2 of CCR5, and as a compensation of this, the insertion
could potentially change the reliance of V3 base and bridging sheet of
gp120 on the CCR5 N-terminus for entry. On the other hand, the
changes in the structure that affect how V3 recognizes CCR5 may
impart a more ﬂexible conformation to the virus. This ﬂexibility may
be essential for engaging CXCR4 as an alternative coreceptor while
retaining its ability to interact with CCR5. It has been suggested that
dual tropic HIV-1 strains may have extreme ﬂexibility to display two
different conformations (Cardozo et al., 2007) or binding sites
(Hartley et al., 2005; Nolan et al., 2008) on the V3 surface in order
to interact with either CCR5 or CXCR4. Our surface electrostatic
potential analysis appeared to support this notion by showing the
presence of both a negative cavity and a strong positively charged V3
tip in the dual tropic variant 48m-18. The positively charged surface
may interact with the unusually anionic surface of CXCR4 (Brelot
et al., 1999). On the other hand, the negative cavity in V3 seems to be
consistent with the proposed negatively charged or neutral nature of
R5 tropic viruses (Basmaciogullari et al., 2002; Cardozo et al., 2007;
Hartley et al., 2005). Further dissecting the possible impact of the
adapted changes associated with the expanded coreceptor utilization
on the ability of V3 to interact with CCR5 or CXCR4 will provideimportant information on the molecular mechanisms and the
structural basis for subtype C HIV-1 coreceptor usage.
In summary, our study provides strong evidence for the molecular
determinants of subtype C HIV-1 dual coreceptor tropism. Speciﬁc
changes in three areas in the V3 domain including residue substitu-
tions or insertions account for the transition from a R5 to R5X4
phenotype. In addition, the increased net charge in V3 is another
feature coupled with the CXCR4 utilization. Our structural modeling
suggested that possible structure alterations in V3 resulted from those
sequence changes, and thus enabling the virus to adopt the structure
required for the R5X4 phenotype. Although this is the only case of
expanded coreceptor usage that was identiﬁed among our Zambian
mother–infant cohort, to our knowledge our study is the ﬁrst to use
cloned viruses to experimentally decipher the molecular determi-
nants of the expanded CXCR4 tropism of subtype C HIV-1 since
previous studies are limited to sequence analyses only. In addition,
our study suggested that the presence of the threemutations in the V3
region may also affect coreceptor usage of other subtype C viruses.
Moreover, the strong homology in the V3 region, particularly the two
amino acid insertions and the T substitution, between our R5X4 tropic
virus and the published subtype C dual or X4 tropic virus sequences
further strengthens our conclusions and reinforces the impact of these
mutations on CXCR4 preference of subtype C viruses. With more
subtype C X4 viruses being identiﬁed, particularly with the emerging
availability of entry inhibitors, more detailed studies on virological
adaptations within subtype C viruses associated with the acquired
ability to use CXCR4 as a coreceptor will be needed to further
elucidate the molecular mechanisms controlling coreceptor prefer-
ence. The panel of genetically related but functionally distinct
chimeric viruses should be useful tools in understanding how speciﬁc
changes in the Env V3 domain favoring coreceptor switch may affect
the biological properties of the virus, and contribute to the
pathogenesis of subtype C HIV-1.
Materials and methods
Cells
293 T, TZM-bl, MT-2, and Ghost 3 or U373-MAGI cell lines which
express speciﬁc coreceptor were obtained from the NIH AIDS
Research and Reference Reagent Program. 293 T and TZM-bl cells
were maintained in Dulbecco's modiﬁed Eagle medium (DMEM) with
10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml
streptomycin. MT-2 cells were maintained in RPMI 1640 medium
with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. Ghost
3 cells expressing CD4 and either CCR5 or CXCR4 were maintained in
DMEM with 10% FBS, 500 μg/ml G418, 100 μg/ml hygromycin B,
penicillin–streptomycin and 1.0 μg/ml puromycin. U373-MAGI-CCR5
and U373-MAGI-CXCR4 cells were propagated in selection medium
consisting of DMEM supplemented with 10% FBS, 200 μg/ml G418,
100 μg/ml hygromycin B and 1.0 μg/ml puromycin. Culture medium
for virus infection and inhibition assays consisted of DMEM with 10%
FBS.
Env cloning, plasmid construction, and mutagenesis
The existing, genetically characterized Env V1–V5 clones from
child 1690 were the source of genetic materials for generation of the
Env chimeras (Zhang et al., 2006). Multiple representatives of Env
clones with the signature sequences were selected from time points
before (42 months) and after (48 months) coreceptor switch. The
chimeric Env expression construct or proviral expression construct
containing patient-derived Env V1–V5 region was generated as
described previously (Zhang et al., 2010). Brieﬂy, Env V1–V5 fragment
from those selected cloneswas ﬁrst introduced into an Env expression
vector, pSRH NLA/S/Av, with the subtype B (NL4-3) backbone. All the
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screened for biological function using the fusion assay as described
previously (Zhang et al., 2010). Finally, the functional envelope
construct was transferred into a proviral expression vector-pNL4-3 A/
S/Av, with NL4-3 viral backbone, resulting in the infectious molecular
clones.
Single and combinations of mutations within V3 region of the virus
were introduced by site-directed mutagenesis using QuickChange II
XL kit (Stratagene). All procedures were performed according to the
manufacturer's protocol. The V3 or V4 region chimeras were
generated by overlapping PCR. Finally, the pSRH NLA/S/Av envelope
construct of a serial of mutants was transferred into the proviral
expression vector-pNL4-3 A/S/Av to generate the infectious molec-
ular clones. The sequences of the resulting chimeras were conﬁrmed
by sequence analysis to ensure that only the desired substitutions
were present.Infectious HIV-1 viral stocks
Wild-type or mutated infectious molecularly cloned viral stocks
were produced by transfection of 293 T cells with relevant proviral
constructs. Nine micrograms of proviral constructs was transfected
into 2.2×106 293 T cells using Fugene 6 (Roche). The resulting
infectious viruses were harvested 48 h post-transfection. Tissue
culture dose for 50% infectivity (TCID50) was determined for each
virus in TZM-bl cells. Viral titer was deﬁned as TCID50/ml.Determination of viral coreceptor utilization
The coreceptor utilization of these mutated chimeric viruses was
ﬁrst tested in Ghost 3 cells that express CD4 and speciﬁc coreceptor,
either CCR5 or CXCR4. These cells contain HIV-2 LTR promoter
cassettes that express green ﬂuorescent protein (GFP) in response to
stimulation with HIV-1 Tat. Equivalent infectious units, 400 TCID50, of
each chimeric provirus from transfected 293T cells as described
previously were added to triplicate wells in a 24-well plate containing
4×104 Ghost cells per well. Ghost cells were assayed for infection by
the observation of GFP expression at 4–5 days post-infection. The
CXCR4 utilization was conﬁrmed by the appearance of syncytia in MT-
2 cells. For MT-2 infection, 500 TCID50 of each chimeric provirus was
added to triplicate wells in a 24-well plate containing 5×104 MT-2
cells per well. On days 6–7 post-infection, cells were scored for
syncytia formation.Entry inhibition assays
Entry inhibitors TAK 779 or JM-2987 (hydrobromide salt of AMD
3100) were obtained from the NIH AIDS research and Reference
Reagent Program. Entry inhibition was examined in TZM-bl or U373-
MAGI-CCR5 or CXCR4 indicator cells in 96-well plates. Brieﬂy, the cells
were pre-treated with 50 μl of 2 μM of TAK 779 or AMD 3100 for
30 min at 37 °C before infection. One hundredﬁfty TCID50 of each virus
(in 50 μl) was then added to TZM-bl cells in triplicate for 72 h at 37 °C
or 100 TCID 50 of each virus was added to U373-MAGI-CCR5 or CXCR4
cells in the presence of 10 μg/ml of DEAE-dextran for 48 h at 37 °C. At
the end of the culture period, the cells were lysed and processed for
luciferase activity (Luciferase Assay System, Promega, Madison,WI) in
TZM-bl cells or β-galactosidase activity (Galaco-Star System, Applied
Biosystems, Bedford, MA) in U373-MAGI-CCR5 or CXCR4 cells.
The percentage of entry inhibition was calculated by the luciferase
or β-galactosidase activity in the presence of the entry inhibitor
relative to that in the absence of inhibitor. Background luminescence
in uninfected wells was subtracted from all experimental wells.Infection assays
One hundred ﬁfty TCID 50 of each virus was used to infect 1×104
U373-MAGI-CCR5 or CXCR4 cells in triplicate in the presence of 10 μg/
ml of DEAE-dextran in a 96-well plate. At 48 h post-infection, the
infection was quantiﬁed by measuring β-galactosidase activity as
described previously.
Positive selection analysis
To identify selection on individual codonswithin V3, we computed
the mean ratio of nonsynonymous to synonymous nucleotide
substitutions (dN/dS) per site using the single-likelihood ancestor
counting (SLAC) method available in the Datamonkey web interface
of the HY-PHY package (Pond and Frost, 2005; Pond et al., 2005). In
each case, this analysis utilized the GTR model of nucleotide
substitution and an input neighbor-joining tree.
Structure modeling of the V3 loop
Structure modeling of the V3 loop for the R5 variant 48m-30 and
the dual tropic variant 48m-18 was performed using the SWISS-
MODEL server [http://swissmodel.expasy.org/; (Arnold et al., 2006)].
The server chose the crystal structure of HIV-1 JR-FL gp120 core
protein as a structural template [Protein Data Bank ID 2B4C; G chain;
(Huang et al., 2005)] for both variants. The root-mean-square
deviation (RMSD) between the model and the template was 0.05 Å
for both coordinates.
The electrostatic potential of variants 48m-30 and 48m-18 was
calculated using PBEQ Solver on CHARMM-GUI [http://www.
charmm-gui.org/; (Jo et al., 2008)] by solving the Poisson–Boltzmann
equation (Im et al., 1998). Model visualizations were made using
PyMOL (DeLano, 2008).
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